Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

NCT05528354 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05528354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05528354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Unknown status
Start date
June 2, 2022
Completion date
December 31, 2025
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell transplantation, tp53